Maryland Attorney General Anthony Brown has joined a coalition of Democratic attorneys general suing the federal government—not to defend civil liberties, but to block federal patient-safety standards grounded in a comprehensive scientific review of pediatric gender medicine.
The lawsuit challenges actions taken by the U.S. Department of Health and Human Services (HHS) after an extensive evidence review raised serious concerns about irreversible harm, weak evidence of benefit, and profound uncertainty surrounding sex-rejecting medical interventions for children.
This dispute is no longer about slogans like “affirming care” or accusations of discrimination. It is about whether the government may restrict irreversible medical interventions on minors when evidence of benefit is thin and evidence of harm is mounting.
The question for Marylanders is straightforward: why is the state’s top law-enforcement officer attempting to stop federal patient-safety standards supported by HHS’s own scientific findings?
On December 18, 2025, HHS announced proposed regulatory actions barring hospitals from performing sex-rejecting pharmaceutical or surgical procedures on minors as a condition of participation in Medicare and Medicaid. The policy applies to patients under 18 and targets interventions intended to align a child’s body with an asserted identity different from their biological sex.
Contrary to activist claims, the rule does not criminalize physicians. It does not regulate adult care. It does not ban counseling, psychotherapy, or mental-health support. And it does not impose criminal penalties of any kind.
Instead, CMS relied on long-standing statutory authority under the Social Security Act to set participation standards necessary to protect patient health and safety—authority it has exercised for decades across a wide range of medical contexts. Because nearly all U.S. hospitals participate in Medicare and Medicaid, the rule is nationally consequential, but legally orthodox.
HHS did not act impulsively or on ideological grounds. The policy followed a comprehensive federal evidence review commissioned under Executive Order 14187 and conducted by HHS’s Office of Population Affairs. The review was not a clinical practice guideline; its purpose was to assess the quality of evidence, ethical considerations, and long-term risks associated with treating gender dysphoria in minors.
Its findings were sobering.
The evidence supporting puberty blockers, cross-sex hormones, and pediatric surgeries was rated low to very low quality. Much of the literature was observational, confounded by bias, plagued by loss to follow-up, and limited to short time horizons.
Crucially, long-term outcomes—fertility loss, sexual function, bone density, cardiovascular risk, and neurological development—remain poorly studied or unknown. By contrast, psychotherapy and watchful waiting showed comparable or better outcomes without exposing children to irreversible harm.
This is the scientific foundation on which HHS acted—and which Anthony Brown’s lawsuit largely ignores.
Far from being an American anomaly, HHS’s caution mirrors decisions made by public-health authorities across Europe.
The United Kingdom’s Cass Review—the most comprehensive independent examination of pediatric gender medicine ever conducted—concluded that the evidence base is “remarkably weak” and that routine medicalization of minors cannot be justified. It recommended psychosocial care as the default approach.
Following similar evidence reviews, Sweden, Finland, Norway, and the UK have all restricted or halted routine medical interventions for minors. These shifts were led by national health services and medical regulators, not conservative politicians or culture-war activists.
Even U.S. media outlets and academic commentators now acknowledge that this is not settled science.
At its core, this debate is not about identity. It is about irreversibility.
Puberty blockers may impair bone density and neurological development. Cross-sex hormones can result in permanent infertility, loss of sexual function, and increased cardiovascular and metabolic risks. Surgeries are irreversible by definition.
The ethical question is simple but unavoidable: should the state permit life-altering medical interventions for children absent strong evidence of net benefit?
Brown’s lawsuit frames the HHS action as an “attack on gender-affirming care.” But it does not seriously engage with the federal evidence review, the Cass Report, European policy reversals, or the problem of irreversibility. Instead, it treats pediatric gender medicine as settled science—precisely what the evidence now contradicts.
Legally, the strategy is to freeze policy at the height of medical enthusiasm rather than adapt to emerging caution. Politically, it puts Maryland at odds with the federal government’s own patient-safety findings.
HHS acted after a comprehensive scientific review. Other advanced democracies reached similar conclusions independently. Anthony Brown’s lawsuit seeks to override that emerging consensus through litigation.
This is not a culture-war skirmish. It is a collision between law, medicine, and the ethical limits of experimental interventions on children—and Maryland’s Attorney General has chosen the wrong side of that line.
Endnotes
- Maryland Attorney General Lawsuit Announcement
Maryland Office of the Attorney General, Attorney General Brown Files Lawsuit Challenging Federal Attack on Gender-Affirming Care (Dec. 2025).
https://oag.maryland.gov/News/Pages/Attorney-General-Brown-Files-Lawsuit-Challenging-Federal-Attack-on-Gender-Affirming-Care-.aspx - HHS December 18, 2025 Announcement
U.S. Department of Health and Human Services, HHS Acts to Bar Hospitals from Performing Sex-Rejecting Procedures on Children (Dec. 18, 2025).
https://www.hhs.gov/press-room/hhs-acts-bar-hospitals-performing-sex-rejecting-procedures-children.html - CMS Statutory Authority
Social Security Act §§ 1861(e)(9), 1871, and 1905(a), authorizing CMS to impose conditions of participation necessary to protect patient health and safety. - Executive Order 14187
Executive Order 14187 (Jan. 28, 2025), directing HHS to conduct a comprehensive review of evidence related to the treatment of gender dysphoria in minors. - HHS Gender Dysphoria Evidence Review (Primary Report)
U.S. Department of Health and Human Services, Office of Population Affairs, Treatment for Pediatric Gender Dysphoria: Evidence Review.
https://opa.hhs.gov/gender-dysphoria-report - HHS Technical Supplement
HHS Office of Population Affairs, Gender Dysphoria Evidence Review: Supplemental Technical Appendix (Nov. 2025).
https://opa.hhs.gov/sites/default/files/2025-11/gender-dysphoria-report-supplement.pdf - Cass Review (United Kingdom)
Independent Review of Gender Identity Services for Children and Young People (The Cass Review), Final Report (UK National Health Service).
Archived version:
https://webarchive.nationalarchives.gov.uk/ukgwa/20250310143933/https://cass.independent-review.uk/home/publications/final-report/ - BBC Coverage of Cass Review Findings
BBC News, What Is the Cass Review and What Does It Mean for Transgender Care?
https://www.bbc.com/news/health-68863594 - European Policy Shifts on Pediatric Gender Medicine
National health authorities in Sweden (Socialstyrelsen), Finland (COHERE Finland), Norway, and the UK have all restricted routine medical interventions for minors following independent evidence reviews between 2020–2024. - City Journal Analysis of HHS Review
City Journal, HHS’s Peer-Reviewed Report on Pediatric Gender Medicine (summary and commentary).
https://www.city-journal.org/article/hhs-peer-reviewed-pediatric-gender-care-report - New York Times on the Cass Review and Evidence Debate
New York Times, New Review Questions Medical Treatments for Transgender Youth (May 13, 2024).
https://www.nytimes.com/2024/05/13/health/hilary-cass-transgender-youth-puberty-blockers.html
Direct Line News is a Maryland-based free-access publication committed to the Republican reform tradition.
About The Author
